Announced Thu, 14 May · 16:23 IST

Outcome of Board Meeting

Pat NegativeRevenue DeclineEbitda Margin CompressionResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+13.7%1-day move

₹497.55

prior close

₹507.10

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+5.8+4.0+4.5+6.5+13.7+15.2+14.1+22.6+25.6+30.6+29.7+13.6+33.9—

Up moveDown movePending

AI summary

Shree Ganesh Remedies Ltd held a Board meeting on May 14, 2026, and approved the audited financial results for Q4 and FY ended March 31, 2026. The company reported standalone revenue from operations of Rs 10,928.58 lakhs, essentially flat compared to Rs 10,859.65 lakhs in FY2025. However, profit after tax declined significantly to Rs 1,777.33 lakhs from Rs 2,309.81 lakhs in the previous year, representing a ~23% drop. Finance costs nearly doubled from Rs 207.73 lakhs to Rs 356.19 lakhs. EPS declined from Rs 17.98 to Rs 13.84 per share. The statutory auditors issued an unmodified (clean) opinion on both standalone and consolidated financials. The company also re-appointed S N D K & Associates LLP as internal auditors for FY 2026-27.

Likely market impact

The stock may face pressure due to significant profit decline despite flat revenue, indicating margin compression. The clean audit opinion provides some comfort to investors regarding financial reporting quality.